Adjuvants Used In Animal Vaccines-Their Formulations and Modes of Action: An Overview

Abstract

Vaccination has proven to be the most effective method for the prevention and control of infectious diseases in the animals and birds. The success of vaccination depends on many factors but one of the important factor is the selection of most suitable and efficient adjuvant. An adjuvant is an ingredient of the vaccine which is used to improve the immune response in the animal’s body to vaccines. The inclusion of adjuvant to the vaccine preparation results in the abrupt stimulation of the immune system, production of the stronger immune response, activation of the specific type of immunity and increasing the half life of vaccine antigen. Previously, the role of adjuvants were poorly understood but with the increasing knowledge of the mechanism of action of adjuvants and the immune system, new adjuvants are being formulated that are safe and most effective against existing and emerging animal diseases. In this review, we will discuss about the current available adjuvants for animal vaccines with focus on their mechanism of action. In addition, we will also learn about the challenges and opportunities in the development of animal vaccine adjuvants.

Keywords

• Adjuvant,
• Vaccine,
• Infectious diseases

Hayvan Aşılarında Kullanılan Yardımcı Maddeler - Formülasyonları ve Etki Yöntemleri: Genel Bir Bakış

Öz

Vaccination has proven to be the most effective method for the prevention and control of infectious diseases in the animals and birds. The success of vaccination depends on many factors but one of the important factor is the selection of most suitable and efficient adjuvant. An adjuvant is an ingredient of the vaccine which is used to improve the immune response in the animal’s body to vaccines. The inclusion of adjuvant to the vaccine preparation results in the abrupt stimulation of the immune system, production of the stronger immune response, activation of the specific type of immunity and increasing the half life of vaccine antigen. Previously, the role of adjuvants were poorly understood but with the increasing knowledge of the mechanism of action of adjuvants and the immune system, new adjuvants are being formulated that are safe and most effective against existing and emerging animal diseases. In this review, we will discuss about the current available adjuvants for animal vaccines with focus on their mechanism of action. In addition, we will also learn about the challenges and opportunities in the development of animal vaccine adjuvants.

Anahtar Kelimeler

• Yardımcı madde,
• Aşı
• Bulaşıcı hastalık,

References

1. [1]. Glenny AT., Pope CG., Waddington H., Wallace U. Immunological notes, XVI1-XXIV. The Journal of Pathology and Bacteriology 1926; 29: 31-40.
2. [2]. Gupta RK. Aluminum compounds as vaccine adjuvants, Advanced Drug Delivery Reviews 1998; 32: 155-172.
3. [3]. Dandashli EA., Zhao Q., Yitta S., Morefield GL., White JL. Hem SL. Effect of thermal treatment during the preparation of aluminum hydroxide adjuvant on the protein adsorption capacity during aging, Pharmacuetical Development and Technology 2002; 7(4): 401-406.
4. [4]. Yau KP., Schulze DG., Johnston CT., Hem SL. Aluminum hydroxide adjuvant produced under constant reactant concentration, Journal of Pharmaceutical Sciences 2006; 95: 1822-1833.
5. [5]. Kool M., Fierens K., Lambrecht BN. Alum adjuvant: Some of the tricks of the oldest adjuvant, Journal of Medical Microbiology 2012; 61(Pt 7): 927-934.
6. [6]. HogenEsch H. Mechanisms of stimulation of the immune response by aluminium adjuvants, Vaccine 2002; 20(Suppl 3): S34-S39.
7. [7]. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson LA. The common vaccine adjuvant aluminum hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism, Infection and Immunology 2001; 69: 1151-1159.
8. [8]. Vecchi S., Bufali S., Skibinski DA., O’Hagan DT., Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations, Journal of Pharmaceutical Sciences 2012; 101: 17-20.

9. [9]. Pini A., Danskin D., Coackley W. Comparative evaluation of the potency of beta-propiolactone inactivated Newcastle disease vaccines prepared from a lentogenic strain and a velogenic strain, Veterinary Record 1965; 77: 127.
10. [10]. Sellers RF., Herniman KAJ. Early protection of pigs against foot and mouth disease, British Veterinary Journal 1974; 130: 440-445.
11. [11]. Sesardic D., Rijpkema S., Patel BP. New adjuvants: EU regulatory developments, Expert Review of Vaccines 2007; 6: 849-861.
12. [12]. Olmedo H., Herrera M., Rojas L., Villalta M., Vargas M., Leiguez E., Teixeria C., Estrada R., Gutierrez JM., Leon G., Montero ML. Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom, Journal of Immunotoxicology 2014; 11(1): 44-49.
13. [13]. He Q., Mitchell AR., Johnson SL., Wagner-Bartek C., Morcol T. Calcium phosphate nanoparticle adjuvant, Clinical and Diagnostic Laboratory Immunology 2000; 7(6): 899-903.
14. [14]. Joyappa DH., Kumar CA., Banumathi N., Reddy GR., Suryanarayana VV. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus, Veterinay Microbiology 2009; 139: 58-66.
15. [15]. Khong H., Overwijk WW. Adjuvants for peptide-based cancer vaccines, Journal for Immuno Therapy of Cancer Immunother Cancer 2016; 4: 56.